A Novel Three-Gene Model Predicts Prognosis and Therapeutic Sensitivity in Esophageal Squamous Cell Carcinoma.

To precisely predict the clinical outcome and determine the optimal treatment options for patients with esophageal squamous cell carcinoma (ESCC) remains challenging. Prognostic models based on multiple molecular markers of tumors have been shown to have superiority over the use of single biomarkers...

Descripción completa

Detalles Bibliográficos
Publicado en:BioMed Research International pp. 1 - 13
Autores principales: Zeng, Fa-Min, He, Jian-Zhong, Wang, Shao-Hong, Liu, De-kai, Xu, Xiu-E., Wu, Jian-Yi, Li, En-Min, Xu, Li-Yan
Formato: pictorial research tables/charts Journal Article
Publicado: Wiley-Blackwell 11/25/2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139838926&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 139838926
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        23146133
        FT2T
      jtl: BioMed Research International
      issn: 23146133
      maglogo: N
    pubinfo:
      dt: 11/25/2019
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        139838926
        139838926
        139838926
        10.1155/2019/9828637
        139838926
      ppf: 1
      ppct: 12
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: A Novel Three-Gene Model Predicts Prognosis and Therapeutic Sensitivity in Esophageal Squamous Cell Carcinoma.
      aug:
        au:
          Zeng, Fa-Min
          He, Jian-Zhong
          Wang, Shao-Hong
          Liu, De-kai
          Xu, Xiu-E.
          Wu, Jian-Yi
          Li, En-Min
          Xu, Li-Yan
        affil: The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, Guangdong, China
      sug:
        subj:
          Transcription Factors Analysis
          Oxidoreductases Analysis
          Cell Adhesion Molecules Analysis
          Tumor Markers, Biological Analysis
          Esophageal Neoplasms Prognosis
          Carcinoma, Squamous Cell Prognosis
          Esophageal Neoplasms Therapy
          Carcinoma, Squamous Cell Therapy
          Human
          Survival
          Gene Expression
          Neoplasm Staging
          Lymph Nodes Pathology
          Neoplasm Metastasis
          ROC Curve
          Regression
          Chemoradiotherapy
      ab: To precisely predict the clinical outcome and determine the optimal treatment options for patients with esophageal squamous cell carcinoma (ESCC) remains challenging. Prognostic models based on multiple molecular markers of tumors have been shown to have superiority over the use of single biomarkers. Our previous studies have identified the crucial role of ezrin in ESCC progression, which prompted us to hypothesize that ezrin-associated proteins contribute to the pathobiology of ESCC. Herein, we explored the clinical value of a molecular model constructed based on ezrin-associated proteins in ESCC patients. We revealed that the ezrin-associated proteins (MYC, PDIA3, and ITGA5B1) correlated with the overall survival (OS) and disease-free survival (DFS) of patients with ESCC. High expression of MYC was associated with advanced pTNM-stage (P=0.011), and PDIA3 and ITGA5B1 were correlated with both lymph node metastasis (PDIA3: P<0.001; ITGA5B1: P=0.001) and pTNM-stage (PDIA3: P=0.001; ITGA5B1: P=0.009). Furthermore, we found that, compared with the current TNM staging system, the molecular model elicited from the expression of MYC, PDIA3, and ITGA5B1 shows higher accuracy in predicting OS (P<0.001) or DFS (P<0.001) in ESCC patients. Moreover, ROC and regression analysis demonstrated that this model was an independent predictor for OS and DFS, which could also help determine a subgroup of ESCC patients that may benefit from chemoradiotherapy. In conclusion, our study has identified a novel molecular prognosis model, which may serve as a complement for current clinical risk stratification approaches and provide potential therapeutic targets for ESCC treatment.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N